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Conclusions: This meta-analysis shows a modest but signiﬁcant 
improvement in overall survival and local failures at the expense of a 
clearly increased severe esophagitis. Difﬁculties of increased treat-
ment frequency and the continuous therapy over weekends make these 
strategies hard to adopt. On the other hand, due to the heterogeneity of 
altered fractionation modalities among the trials included, our results 
should be considered with caution and must be interpreted as an hy-
pothesis generator.
TRIAL n HFRT type Chemotherapy Median OS p
Ball 204 60 Gy in 3 wks Weekly CBDCA 14.7 vs 15.4 ns
Saunders 
(CHART) 563
54 Gy in  
12 consecutive days No CT 16.5 vs 13 0.008
Bonner 99 60 Gy in 4 wks split CDDP-VP16 11.6 vs 8.6 ns
ECOG 2597 112 57.6 Gy in  13 consecutive days
CBDCA-paclitaxel 
before RT 20.3 vs 14.9 ns
RTOG 8808 458 69.6 Gy in 6 wks CDDP-VBL 12 vs 11.4 ns
Schild 234 60 Gy in 4 wks split CDDP-VP16 14 vs 15 ns
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Predictors of survival for non-small-cell lung cancer patients with 
brain metastases treated with whole brain radiation therapy: 
pooled data from two randomized trials
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Background: A commonly used prognostic classiﬁcation for brain 
metastasis patients is the Recursive Partitioning Analysis (RPA) clas-
siﬁcation developed with data from patients enrolled in RTOG trials 
from 1979 to 1993, which includes performance status, age, presence 
of extracranial metastasis and control of primary disease. The purpose 
of the current study was to determine if additional variables are signiﬁ-
cant independent predictors of survival in NSCLC patients with brain 
metastases.
Methods: In protocol 9801, 401 pts with brain metastases from any 
primary tumor were randomized to whole brain radiation therapy 
(WBRT, 30 Gy/10 fractions) or WBRT+MGd, 5 mg/kg qd x 10 days. 
The subgroup of 251 pts with NSCLC is included in this analysis. 
In protocol 0211, 554 pts with brain metastases from NSCLC were 
randomized to the same treatments. In both studies, eligibility included 
a KPS≥70, no liver metastases, and ≤1 site of extracranial metastasis. 
Univariate and stepwise multivariate Cox analyses were carried out 
using baseline clinical variables, laboratory values, neurocognitive test 
scores and survival follow-up data. Hazard ratios (HR) less than 1 favor 
the speciﬁed group.
Results: 805 patients, with a median age of 59 years, 44.6% female, 
55.4% male, 53.3% adenocarcinoma, 19.3% NSCLC, not otherwise 
speciﬁed (NOS), 13.4% squamous cell, 10.6% large cell, 0.9% bron-
choalveolar, 19.7% single brain metastasis, 80.3% multiple brain me-
tastases, 47% extracranial metastases, and 84% presentation with neu-
rologic deﬁcits were randomized to WBRT (N=403) or WBRT+MGd 
(N=402). Time to neurologic progression in the WBRT+MGd group 
was 15.4 months, signiﬁcantly longer than the 9.0 months for the 
WBRT alone group, p=0.016, HR=0.74 (95% CI 0.57-0.95). Median 
survival overall was 5.5 months, without statistically signiﬁcant differ-
ence between treatment groups. Univariate predictors of survival were 
age, performance status, sex, histology, geographic region, low LDH, 
high LDH, low albumin, low Hgb, impaired memory (HVLT recall 
and recognition tests), verbal ﬂuency (COWA test), executive function 
(Trailmaking test B), number of impaired neurocognitive tests, and 
smoking history. RPA class was borderline predictive in a univariate 
model (HR=1.27, P=0.056 for RPA class II vs I). In a stepwise model 
of all variables, age ≥65 (HR=1.34, P=0.005), KPS 90-100 (HR=0.70, 
P<0.001), multiple brain metastases (HR=1.27, P=0.035), presence 
of extracranial metastases (HR=1.21, P=0.036), male sex (HR=1.34, 
P=0.001), non-small-cell histology (NOS) (HR=1.37, P=0.005), 
Canada (HR=1.28, P=0.013), high baseline LDH (HR=1.39, P=0.023), 
low baseline LDH (HR=0.49, P=0.046), low baseline albumin (HR 
1.64, P<0.001), current smoker (HR=1.29, P=0.009) were independent 
predictors of survival. 
Conclusions: In two large randomized trials of patients with NSCLC 
and brain metastases, older age, poorer performance status, multiple 
brain metastases, presence of extracranial metastases, male sex, 
elevated LDH and albumin, current smoking status, and residence in 
Canada were signiﬁcant predictors of shorter survival. These variables 
may provide more predictive power than RPA class for future random-
ized trials in NSCLC patients with brain metastases that have survival 
as an endpoint.
PD5-3-1 NSCLC-Surgery, Thu, 12:30 - 14:15
Role of intraoperative ultrasound for mediastinal staging in non-
small cell lung cancer surgery
Ilic, Nenad1 Petricevic, Ante1 Banovic, Josip1 Frleta Ilic, Nives2 
Tripkovic, Andro1 Grandic, Leo1 Kotarac, Slavica3 Juricic, Josko1 
1 University Surgical Hospital, Split, Croatia 2 Oncology Dept., Clinical 
Hospital, Split, Croatia 3 Pulmology Dept., Clinical Hospital, Split, 
Croatia 
Objectives: The extend of lymph node involvement in patients with 
non-small cell lung cancer (NSCLC) is the most important prognostic 
factor and inﬂuences multimodality treatment. We studied safety, ac-
curacy and characteristics of intraoperative ultrasound (US) guided sys-
tematic mediastinal nodal dissection in patients with resected NSCLC.
Methods: Intraoperative hand held ultrasound probe was used in sys-
tematic mediastinal nodal dissection in 54 patients after radical surgery 
for NSCLC. Mapping of the lymph nodes by their number and station 
followed by histopathologic evaluation was performed. Data were com-
pared with 58 patients who underwent lung resections and systematic 
mediastinal nodal dissection for NSCLC within the same time period at 
our institution. Statistical analysis was carried out.
Results: The surgical procedure used depended on the extent of the 
disease, as well as the cardiopulmonary reserve of the patients and was 
comparable in both groups. Operating time was prolonged for 12 (6 
- 20) minutes in patients with US guided mediastinal nodal dissection, 
but number and stations of evaluated lymph nodes was signiﬁcantly 
higher (p>0.001) at the same group of patients. Skip nodal metastases 
were found in 24% of patients without N1 nodal involvement. Standard 
staging system seemed to be improved in US guided mediastinal 
lymphadenectomy patients. Complications rate showed no difference 
between analyzed groups of patients.
Conclusion: Higher number and location of analyzed mediastinal 
nodal stations in patients with resected NSCLC using hand held ultra-
sound probe suggested to be of great oncology signiﬁcance. Procedure 
Copyright © 2007 by the International Association for the Study of Lung Cancer S479
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
showed improved safety and higher accuracy. Our results indicate that 
intraoperative US may have important staging implication. 
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Prognostic value of the number of examined lymph nodes in totally 
resected Non-Small-Cell Lung Cancer
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Background: Surgery is the gold standard for cure in resectable Non-
Small-Cell Lung Cancer (NSCLC). Pneumonectomy and lobectomy 
are performed along with mediastinal lymph node dissection to allow 
pTNM staging. In other tumor types including colon and gastric cancer, 
it has been demonstrated that the number of examined lymph node is 
an independent prognostic factor of survival, whatever the lymph node 
involvement. We retrospectively analyzed 218 patients with a totally 
resected NSCLC and looked at the prognostic value of the number of 
lymph nodes examined on the resected specimen. 
Methods: Consecutive cases from 01/2001 to 12/2004 included 81% 
men, median age 61, Squamous histology 50%, Adenocarcinoma 39%. 
There were 44% pTNM stage I, 29% stage II and 27% stage III, (54% 
pN0, 30% pN1 and 16% pN2), median follow-up 38 months. Surgery 
consisted in pneumonectomy (33%), lobectomy or bilobectomy (67%). 
Only 18 patients (8.6%) received adjuvant chemotherapy.
Results: The median number of lymph nodes examined was 7 (1-48) 
(pneumonectomy, median of examined lymph nodes 10, lobectomy/
bilobectomy, 6 examined lymph nodes). Three groups were deﬁned 
according to the number of examined lymph nodes to assess a possible 
prognostic value: 0-4 (group 1), 5-8 (group 2), 9 or more(group 3). In 
the overall population, no difference was seen among the three groups 
on Relapse-Free Survival (RFS, p=0.48), Lung cancer Speciﬁc Survival 
(LCSS, p=0.44) and Overall Survival (OS, P=0.63). In stage pN1, the 
number of examined lymph nodes if less than 5 had a signiﬁcant impact 
on RFS (p=0.0003), on OS (p=0.014), and on LCSS (p=0.028). No 
difference was seen in stage pN0 and pN2. Based on the present study, 
patients resected for Stage pN1 with less than 5 lymph nodes examined 
on the resected specimen have a poor outcome, behaving as patients 
with stage pN2 and actually may be understaged: RFS 7.2 vs 7.6 
months, LCSS 23.5 vs 18.7 months, OS 21.6 vs 18.5 months in pN2 vs 
pN1 with less than 5 examined lymph nodes respectively. 
Conclusion: A minimum of 5 lymph nodes should be recommended 
for pathologic examination to provide proper staging in stage pN1 
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Time course of the stimulating effect of serum on lung cancer cell 
proliferation after lung resection
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Purpose: Operative stress can alter the blood levels of various physi-
ologically active substances (cytokines, growth factors, etc.), and thus 
potentially affect cancer cell proliferation. How the combination of 
changes in blood levels of these substances affects cancer cells has not 
been adequate addressed. In an in vitro study we previously reported 
that human serum obtained immediately after lung resection surgery 
stimulated lung cancer cell proliferation compared to that obtained 
before surgery. Here we investigated the time course of the stimulation 
capacity of serum for cancer cell proliferation in the early postoperative 
period.
Methods: The subjects were 10 patients undergoing lung cancer surgery. 
Blood was sampled from each subject immediately before surgery and 
immediately, one day, one week, and two weeks after surgery. Serum 
derived from each blood sample was frozen and stored. EBC-1, a human 
NSCLC culture cell line, was used for the study. Cells were exposed to 
serum (collected at varying points of time before and after surgery) at a 
concentration of 10% for 48 hours. MTT assay was conducted thereafter 
to evaluate cell proliferation, with absorbance (O.D.) measured at 540 
nm (control: 630 nm) using a microplate reader. The percent stimulation 
of cell proliferation with postoperative serum compared with control 
(preoperative) serum was calculated using the formula 100 x (postopera-
tive O.D. - preoperative O.D.)/preoperative O.D.
Results: Serum collected at each time point (immediately, one day, one 
week, and two weeks) after surgery signiﬁcantly stimulated the pro-
liferation of EBC-1 compared to preoperative serum. Serum collected 
immediately after surgery showed the highest percent stimulation of 
cell proliferation, and this effect tended to decrease gradually with time 
after surgery. However, even serum collected two weeks after surgery 
still signiﬁcantly stimulated cell proliferation compared to preoperative 
serum. 
PD5-3-4 NSCLC-Surgery, Thu, 12:30 - 14:15
The impact of multiplicity of metastatic nodal stations on survival 
in surgically resected non-small cell lung cancer patients: Is N2 
disease really different from N1 disease?
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Background: The aim of the study was to identify the common factors 
which affect survival of surgically resected non-small cell lung cancer 
(NSCLC) patients with N1 and N2 disease.
Methods: A retrospective review was performed in NSCLC patients 
who underwent primary surgical resection from Jan 2000 to Sep 2006. 
The inclusion criteria were patients with 1) pathologically conﬁrmed 
N1 and N2 disease, 2) pathologic T1 to T3 disease, 3) no history of 
neoadjuvant chemotherapy, and 4) complete mediastinal lymphad-
enectomy. During the study period 468 NSCLC patients with nodal 
metastasis were operated on in our hospital. According to the selection 
criteria, 281 patients (60.0%) were included in the study. There were 
132 patients with N1 disease (N1 group) and 149 patients with N2 dis-
ease (N2 group). The median follow-up period was 22 months (1 ~ 81 
months) and complete follow-up was possible in 269 patients (95.7%).
Results: Lobectomy was performed in 195 patients (69.4%), bilobec-
tomy in 43 (15.3%) and pneumonectomy in 43 (15.3%). Complete 
resection was possible in 274 patients (97.5%) and operative mortality 
